IFNG and neoplasm: Jiang et al. reported that linking Hsp70 to the tumor antigen Mage-a1 markedly improved protein vaccine performance, including heightened antigen-specific antibodies, IFN-γ release, CTL function, and antitumor protection against Mage-a1-positive tumors, outperforming Mage-a1 alone or mixed with Hsp70 in mice [17].